Bringing together drug discovery company Evotec, pharmaceutical company Bristol Myers Squib, and leading British universities, the $20 million (£16 million) beLAB1407 partnership seeks to identify novel disease modifying therapeutic targets and platforms early on, and to develop them into new biotech spinouts.